High-dose methotrexate toxicity remains a major challenge in oncology, often requiring rapid, informed clinical decisions. This webinar will explore why early intervention is important and how proactive management strategies can transform the current wait and-watch approach, helping clinicians improve patient outcomes.

TOPICS COVERED

Innovation in rare cancer care and methotrexate toxicity management is transforming how clinicians approach complex oncology challenges. This webinar will examine how policy, science, and clinical practice intersect to drive earlier and more effective interventions.

Faculty experts will discuss the evolving landscape of rare cancer legislation, the critical importance of timely intervention in cases of delayed methotrexate elimination, and how proactive management can help prevent methotrexate-induced kidney injury. The session will also showcase MTXPK.org, a tool designed to support timely, data-driven decision-making in clinical practice.

By reinforcing the value of anticipation over reaction, the programme highlights how early intervention and innovation can improve patient outcomes and redefine standards of care in oncology.

Participation in this event is accredited by the Royal College of Pathologists, and delegates will receive a certificate of attendance to claim CPD credit.

WHO SHOULD ATTEND?

This webinar is organised and funded by SERB Pharmaceuticals and is intended for healthcare professionals involved in the use of high-dose methotrexate and the management of methotrexate-related toxicity resulting from delayed elimination.

SPEAKERS

• Andrew Davies | University Hospital Southampton NHS Foundation Trust, Southampton, UK
• Scott Arthur | Member of UK Parliament
• Sandip Mitra | Manchester University Hospitals, Manchester, UK
• Laura Ramsey | Children’s Mercy Kansas City, MO, USA

For more information, please contact Eleanor Pearse at [email protected].

UK-VRX-2500060 | Date of preparation: November 2025